title: Cisplatin-induced peripheral neuropathy: neuroprotection by erythropoietin without affecting tumour growth.
abstract: This study examined the dose-dependent efficacy of erythropoietin (EPO) for preventing and/or treating cisplatin (CDDP) induced peripheral neurotoxicity (CINP), and its influence on tumour treatment and growth. Rats received eight intraperitoneal (ip) injections of 2 mg/kg CDDP twice weekly. EPO co-administered (50 or 10 microg/kg ip, three times/week) had a dose-dependent effect, partially preventing CINP, but 0.5 microg/kg ip was not effective. The neuroprotective effect lasted at least 5 weeks after the last dose of EPO and CDDP. In addition, EPO (50 microg/kg ip three times/week) after the last injection of CDDP still induced a significant recovery of CINP. In a separate experiment in rats bearing mammary carcinoma EPO treatment (50 microg/kg ip) given concurrently with CDDP (1.0 and 1.5 mg/kg twice a week for four weeks) was neuroprotective without influencing the effectiveness of the treatment or tumour growth. EPO thus appears to be an effective neuroprotectant that does not interfere with tumour treatment.
authors.affiliation: Mario Negri Institute of Pharmacological Research, Milan, Italy.
authors.forename: Roberto
authors.initials: R
authors.lastname: Bianchi
authors.forename: Alessandra
authors.initials: A
authors.lastname: Gilardini
authors.forename: Virginia
authors.initials: V
authors.lastname: Rodriguez-Menendez
authors.forename: Norberto
authors.initials: N
authors.lastname: Oggioni
authors.forename: Annalisa
authors.initials: A
authors.lastname: Canta
authors.forename: Tina
authors.initials: T
authors.lastname: Colombo
authors.forename: Giulia
authors.initials: G
authors.lastname: De Michele
authors.forename: Sara
authors.initials: S
authors.lastname: Martone
authors.forename: Alessandra
authors.initials: A
authors.lastname: Sfacteria
authors.forename: Giuseppe
authors.initials: G
authors.lastname: Piedemonte
authors.forename: Giovanni
authors.initials: G
authors.lastname: Grasso
authors.forename: Patrizia
authors.initials: P
authors.lastname: Beccaglia
authors.forename: Pietro
authors.initials: P
authors.lastname: Ghezzi
authors.forename: Maurizio
authors.initials: M
authors.lastname: D'Incalci
authors.forename: Giuseppe
authors.initials: G
authors.lastname: Lauria
authors.forename: Guido
authors.initials: G
authors.lastname: Cavaletti
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000009:adverse effects*; D002455:Cell Division / Q000187:drug effects; D002945:Cisplatin / Q000009:adverse effects*; D004305:Dose-Response Relationship, Drug; D004921:Erythropoietin / Q000627:therapeutic use*; D005260:Female; D006400:Hematocrit; D006614:Hindlimb; D008325:Mammary Neoplasms, Experimental / Q000188:drug therapy* / Q000473:pathology; D009431:Neural Conduction / Q000187:drug effects; D010523:Peripheral Nervous System Diseases / Q000139:chemically induced* / Q000517:prevention & control; D051381:Rats; D017208:Rats, Wistar
chemical_list: D000970:Antineoplastic Agents; D004921:Erythropoietin; D002945:Cisplatin